Biography

Dr. Alcendor completed his post-graduate studies at the NIH and Johns Hopkins University, in Baltimore Maryland indepartments of Molecular Virology and Viral Oncology respectively.
Dr. Alcendor was alsoaresearch consultant to theViral Vector Core Laboratory in Viral Oncology, at Johns Hopkins, and a Simian Cytomegalovirus Expert for the FDA,
Division of Vaccine Injury and Compensation Program for the Department of Health and Human Services in Rockville, Maryland. He is a mentor for the FDA Office of Minority Health, Health Disparities Fellowship. He has also selected as a Minority Scholar in Cancer Research by the American Association for Cancer Research (AACR). He received the Nashville Business Journal Health Care Hero Award in Research. He is also a committee member on the independent Research Evaluation and Decision Panel (REDP) for the AIDS Cancer and Specimen Resource of the NCI-AIDS
Malignancy Program. He is a Brain-on-chip investigator in partnership with Vanderbilt and the Cleveland Clinic. He was recently funded to develop the Blood-Retinal-Barrier on a Chip with implications for ocular disease. He is a Research Liaison for FDA Office of Minority Health MOU with Meharry Medical College. He is a consultant and voting member on the FDA Antiviral Drug Advisory Committee. Dr. Alcendor research interest involves KSHV Regulation of Fibulins in Kaposi’s sarcoma: Implications for the Role of Extracellular Matrix Proteins in Tumorigenesis (AIDS related malignancy); and Models for Cytomegalovirus Induced Congenital Disease and its impact on the blood-brain and retinal barriers.
Keywords: KSHV, Kaposi’s sarcoma, AIDS, AIDS related malignancies, extracellular matrix,
galectins, Blood-brain-barrier, Blood Retinal-Barrier, microfluidics,